ONCAlert | Upfront Therapy for mRCC

Use of Sacituzumab Govitecan in Metastatic Urothelial Carcinoma

Scott T. Tagawa, MD
Published Online: 12:55 PM, Mon September 30, 2019


Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian/Weill Cornell Medical Center, discusses data from the phase II TROPHY-U-O1 trial in patients with metastatic urothelial cancer, presented at the ESMO Congress 2019.

These data demonstrated that a cohort of patients with metastatic disease who had progressed on platinum-based regimens or immunotherapy experienced an overall response rate (ORR) of 29% with treatment of sacituzumab govitecan. These were heavily pretreated patients, who received an average of 4 prior lines of therapy, says Tagawa.

The ORR consisted of 2 complete responses, and 6 confirmed partial responses. Moreover, patients with liver metastases (n = 23) had an ORR of 25.0%. In terms of safety, the antibody-drug conjugate was found to be well tolerated with a manageable and expected safety profile. Notably, these results were consistent with prior findings which demonstrated a 31% ORR in 45 patients with pretreated metastatic urothelial carcinoma, says Tagawa.

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.